Prevention of neuroinflammation associated memory loss using nutraceutical compositions
Inventors
Ichim, Thomas E. • Ramos, Famela • Veltmeyer, James • Dixon, Timothy G.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11957727-B2
Publication Date
2024-04-16
Expiration Date
Abstract
Disclosed are means, methods, and therapeutic compositions for prevention of memory loss during situations of neuroinflammation. In one embodiment the invention teaches administration of the therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal suffering from inflammation in order to preserver memory function.
Core Innovation
The document describes preventing neuroinflammation-associated memory loss using a nutraceutical composition. The composition includes pterostilbene, thymoquinone, sulforaphane, and epigallocatechin-3-gallate/green tea extract (EGCG), and a patient suffering from inflammation associated memory dysfunction is identified and the therapeutic combination is administered at a dosage and frequency intended to inhibit the dysfunction.
The background rationale links neuroinflammation to memory dysfunction and describes microglial activation as part of that process. The document further describes indolamine 2,3-deoxygenase (IDO) metabolite imbalance, including kynurenine-related metabolites such as quinolinic acid and kynurenine, in association with the memory dysfunction.
Supporting results are summarized using an LPS-induced memory loss model in mice. Pretreatment with the ingredient combination reduces the LPS-induced memory loss and reduces brain IL-6 cytokine production measured by ELISA.
Claims Coverage
The partial claims content provides one independent claim covering a patient-identification and administration method using a four-ingredient therapeutic combination, with dependent claim refinements focusing on microglial activation markers and an etiological link to indolamine 2,3-deoxygenase metabolite production.
Identifying a patient with inflammation associated memory dysfunction and administering an effective nutraceutical combination
Identifying a patient suffering from inflammation associated memory dysfunction; administering a composition comprising epigallocatechin-3-gallate or a green tea extract containing it, thymoquinone or a Nigella sativa extract containing it, sulforaphane or a broccoli extract containing it, and pterostilbene or a blueberry extract containing it; wherein the therapeutic combination is administered at a dosage and frequency to effectively inhibit inflammation associated memory dysfunction in the patient.
Defining neural inflammation as microglial activation
Further defining that the neural inflammation is microglial activation.
Microglial activation via HLA II upregulation
Defining microglial activation as upregulation of HLA II on microglia.
Microglial activation via IL-10 production upregulation
Defining microglial activation as upregulation of IL-10 production from microglia.
Microglial activation via nitric oxide production upregulation
Defining microglial activation as characterized by upregulation of nitric oxide production.
Etiological treatment when dysfunction is caused by enhanced indolamine 2,3-deoxygenase metabolites
Treating inflammation associated memory dysfunction caused by enhanced production of indolamine 2,3-deoxygenase metabolites.
Across the provided claim set, the method centers on inhibiting inflammation associated memory dysfunction in a patient by administering a four-ingredient combination. Dependent claims refine neuroinflammation as microglial activation via specific marker and function readouts and relate the dysfunction to enhanced indolamine 2,3-deoxygenase metabolite production.
Stated Advantages
Inhibit inflammation associated memory dysfunction.
Reduces LPS-induced memory loss in mice.
Reduces brain IL-6 cytokine production.
Documented Applications
Use of the composition to prevent neuroinflammation-associated memory loss and treat inflammation associated memory dysfunction in an identified patient.
Reduction of LPS-induced memory loss in mice following pretreatment with the ingredient combination.
Measurement and reduction of brain IL-6 cytokine production by ELISA.
Interested in licensing this patent?